Dyadic International, Inc. is a biotechnology company that develops microbial-based technologies for producing proteins and other biological materials. Its platforms are designed to enable the cost-effective development and manufacture of vaccines, therapeutic proteins, enzymes, and other biologic products.
The company’s technology portfolio includes the C1 protein-production platform, which uses a proprietary fungal microorganism to produce recombinant proteins, and additional microbial expression systems intended to support applications in biopharmaceuticals, animal health, food and nutrition, and industrial biotechnology. Dyadic also develops its own product candidates and works with commercial, academic, and government partners to apply its platforms to vaccines, antibodies, enzymes, and other proteins.
Founded in 1979 and headquartered in Jupiter, Florida, Dyadic has pursued partnerships and technology applications serving markets in North America, Europe, and other international regions. The company is led by founder Mark Emalfarb, who has served as its chief executive officer and has been associated with the development and commercialization of Dyadic’s microbial protein-expression technologies.
AI Generated. May Contain Errors.
